Exploring the Influence of Glucagon-like Peptide -1 (GLP-1) Medications on Food Cravings, Food Selection, and Food Intake Following Exposure to Food Advertisements

NCT07505134 | Not Yet Recruiting

• 1 other identifier: STUDY00028881
• Study Type: interventional
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this randomized control trial is to compare how food cravings, food selection, and food consumption change in response to frequent food advertisements compared to non-food advertisements in adults taking GLP-1 (weight loss) medications. The primary question we aim to answer is: do GLP-1 medications reduce an individual's vulnerability to external triggers that drive food cravings and consumption? Participants will:

• report daily food consumption for a total of 10 days,
• receive eight daily prompts to view food or non-food related advertisements, and respond to a short 9-question survey for 7 days,
• answer several questionnaires,
• and complete two in-person visits to complete a virtual reality food selection task.

Conditions

GLP - 1

Keywords

GLP-1; Food choice; Cravings; Food cue reactivity

Outcome Measures

Primary Outcomes (5)

• Mean food cue reactivity scores in the afternoon

  Average scores of craving levels for each group following afternoon advertisement viewing sessions

  7-day period of all afternoon survey responses

• Mean food cue reactivity scores in the morning

  Average scores of craving levels for each group following morning advertisement viewing sessions

  7-day period of all morning survey responses

• Mean food cue reactivity scores in the evening

  Average scores of craving levels for each group following evening advertisement viewing sessions

  7-day period of all evening survey responses

• Mean food cue reactivity scores overall

  Average scores of craving levels for each group over all viewing sessions

  7-day period of all survey responses

• Energy density of consumed foods

  The energy density profile of foods consumed each day

  7 days

Secondary Outcomes (5)

• Change from baseline in energy density of foods selected in the virtual buffet

  Baseline and 7 days

• Changes in food noise since being on medication questionnaire

  Baseline

• Changes in reasons for purchasing foods questionnaire

  Baseline

• Individual Food Cue Responsiveness--Trait

  Baseline

• Change in brand familiarity, liking, and/or craving

  Baseline and 7 days

Study Arms (2)

Food advertisement group

EXPERIMENTAL

Advertisements viewed daily by this group will be food and/or beverage products

Behavioral: Food advertisements

Tech advertisement group

PLACEBO COMPARATOR

Individuals in this group will only receive tech-related advertisements daily

Behavioral: Tech advertisements

Interventions

Food advertisements BEHAVIORAL

Videos and images of food and beverage advertisements from popular brands and/or restaurants

Food advertisement group

Tech advertisements BEHAVIORAL

Video and photo advertisements of popular tech tools

Tech advertisement group

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adults (18+) with overweight or obesity (BMI \>25 kg/m2)
• On an injectable form of tirzepatide GLP-1 medication at a minimum dose of 7.5 mg, taking it as prescribed by their doctor
• Not currently taking an incretin-based medication at baseline other than the GLP-1 medication
• Fluent in English

You may not qualify if:

• Do not have consistent access to a smart phone that can access the study software
• Diagnosed with cognitive or physical disability or epilepsy
• Adults taking a compound GLP-1

Sponsors & Collaborators

• Penn State University: lead
• Penn State Health: collaborator

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor and Director of the Health, Ingestive Behavior, and Technology Lab

Study Record Dates

• First Submitted: March 17, 2026
• First Posted: April 1, 2026
• Study Start: May 1, 2026
• Primary Completion: August 1, 2026
• Study Completion (Estimated): September 1, 2026
• Last Updated: May 1, 2026

Record last verified: 2026-04